Related references
Note: Only part of the references are listed.565 Novel Infliximab (IFX) and Antibody-to-Infliximab (ATI) Assays are Predictive of Disease Activity in Patients With Crohn's Disease (CD)
Brian G. Feagan et al.
GASTROENTEROLOGY (2015)
1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial
Niels Vande Casteele et al.
GASTROENTEROLOGY (2015)
Tu1147 Serum Adalimumab Levels and Antibodies Correlate With Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients With Inflammatory Bowel Disease
Andres J. Yarur et al.
GASTROENTEROLOGY (2015)
A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's disease
B. G. Levesque et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2014)
Biological Agents for Moderately to Severely Active Ulcerative Colitis A Systematic Review and Network Meta-analysis
Silvio Danese et al.
ANNALS OF INTERNAL MEDICINE (2014)
Treatment algorithms in Crohn's - Up, down or something else?
Ophelie Antunes et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2014)
Novel concepts in inflammatory bowel disease
G. W. Moran et al.
BRITISH MEDICAL BULLETIN (2014)
Association Between Pharmacokinetics of Adalimumab and Mucosal Healing in Patients With Inflammatory Bowel Diseases
Xavier Roblin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Postoperative Therapy With Infliximab Prevents Long-term Crohn's Disease Recurrence
Miguel Regueiro et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2014)
Dose optimization is effective in ulcerative colitis patients losing response to infliximab: A collaborative multicentre retrospective study
Monica Cesarini et al.
DIGESTIVE AND LIVER DISEASE (2014)
Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target
Mariangela Allocca et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2014)
Increased Effectiveness of Early Therapy With Anti-Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease
Thomas D. Walters et al.
GASTROENTEROLOGY (2014)
Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
Remo Panaccione et al.
GASTROENTEROLOGY (2014)
Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2014)
Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt et al.
GUT (2014)
Lemann Index assessment over time in Crohn's disease patients treated with anti TNFs: a pilot observational cohort study
G. Fiorino et al.
JOURNAL OF CROHNS & COLITIS (2014)
Optimising post-operative Crohn's disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study
M. A. Kamm et al.
JOURNAL OF CROHNS & COLITIS (2014)
High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment
Fernando Magro et al.
JOURNAL OF CROHNS & COLITIS (2014)
Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases
William J. Sandborn et al.
JOURNAL OF CROHNS & COLITIS (2014)
Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy
Michael Sherman et al.
JOURNAL OF DIGESTIVE DISEASES (2014)
Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2014)
C-reactive protein is an indicator of serum infliximab level in predicting loss of response in patients with Crohn's disease
Toshifumi Hibi et al.
JOURNAL OF GASTROENTEROLOGY (2014)
Therapeutic drug monitoring in patients with inflammatory bowel disease
Andres J. Yarur et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease
Sara Renna et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Predictors of relapse in patients with Crohn's disease in remission after 1 year of biological therapy
T. Molnar et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
R. Khanna et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2013)
Impact of Antibodies to Infliximab on Clinical Outcomes and Serum Infliximab Levels in Patients With Inflammatory Bowel Disease (IBD): A Meta-Analysis
Kavinderjit S. Nanda et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial
Edoardo Savarino et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient
Niels Vande Casteele et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2013)
Efficacy and safety of infliximab as continuous or intermittent therapy in patients with moderate-to-severe plaque psoriasis: results of a randomized, long-term extension trial (RESTORE2)
K. Reich et al.
BRITISH JOURNAL OF DERMATOLOGY (2013)
Addition of an Immunomodulator to Infliximab Therapy Eliminates Antidrug Antibodies in Serum and Restores Clinical Response of Patients With Inflammatory Bowel Disease
Shomron Ben-Horin et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2013)
Early Administration of Azathioprine vs Conventional Management of Crohn's Disease: A Randomized Controlled Trial
Jacques Cosnes et al.
GASTROENTEROLOGY (2013)
Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
Julian Panes et al.
GASTROENTEROLOGY (2013)
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
Xavier Hebuterne et al.
GUT (2013)
Evolving Definitions of Remission in Crohn's Disease
Remo Panaccione et al.
INFLAMMATORY BOWEL DISEASES (2013)
Prevention of Postoperative Recurrence of Crohn's Disease: What Does the Evidence Support?
Alan C. Moss
INFLAMMATORY BOWEL DISEASES (2013)
Effect of Thalidomide on Clinical Remission in Children and Adolescents With Refractory Crohn Disease A Randomized Clinical Trial
Marzia Lazzerini et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD
Pauliina Molander et al.
JOURNAL OF CROHNS & COLITIS (2013)
When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel
Valerie Pittet et al.
JOURNAL OF CROHNS & COLITIS (2013)
Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease
Martin Bortlik et al.
JOURNAL OF CROHNS & COLITIS (2013)
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
Laurent Peyrin-Biroulet et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn's Disease
Francesca Zorzi et al.
PLOS ONE (2013)
Has There Been a Change in the Natural History of Crohn's Disease? Surgical Rates and Medical Management in a Population-Based Inception Cohort from Western Hungary Between 1977-2009
Peter Laszlo Lakatos et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Surgery in a Population-Based Cohort of Crohn's Disease From Olmsted County, Minnesota (1970-2004)
Laurent Peyrin-Biroulet et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2012)
Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
Ingrid Ordas et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
Paul Rutgeerts et al.
GASTROENTEROLOGY (2012)
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
William J. Sandborn et al.
GASTROENTEROLOGY (2012)
Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
Natalie A. Molodecky et al.
GASTROENTEROLOGY (2012)
Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health
Laurent Peyrin-Biroulet et al.
GUT (2012)
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)
Simon P. L. Travis et al.
GUT (2012)
High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: Results of a meta-analysis of clinical trials
Tessa E. H. Romkens et al.
INFLAMMATORY BOWEL DISEASES (2012)
Paradoxical inflammation induced by anti-TNF agents in patients with IBD
Isabelle Cleynen et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2012)
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab
U. Kopylov et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy
S. Danese et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis
Sandro Ardizzone et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
Walter Reinisch et al.
GUT (2011)
Development of the Crohn's Disease Digestive Damage Score, the Lemann Score
Benjamin Pariente et al.
INFLAMMATORY BOWEL DISEASES (2011)
Results from the 2nd Scientific Workshop of the ECCO (I): Impact of mucosal healing on the course of inflammatory bowel disease
Laurent Peyrin-Biroulet et al.
JOURNAL OF CROHNS & COLITIS (2011)
Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
A. W. G. Waugh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
The Impact of Thiopurines on the Risk of Surgical Recurrence in Patients With Crohn's Disease After First Intestinal Surgery
Pavol Papay et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
Stefan Schreiber et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Concepts and Lessons for Drug Development
Diane R. Mould et al.
BIODRUGS (2010)
Mucosal Healing Predicts Sustained Clinical Remission in Patients With Early-Stage Crohn's Disease
Filip Baert et al.
GASTROENTEROLOGY (2010)
Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates
A. V. Ramadas et al.
GUT (2010)
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
A. Dignass et al.
JOURNAL OF CROHNS & COLITIS (2010)
Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α
David Shealy et al.
MABS (2010)
Clinical implications of mucosal healing for the management of IBD
Guillaume Pineton de Chambrun et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review
Javier P. Gisbert et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis
Adedigbo A. Fasanmade et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Infliximab Prevents Crohn's Disease Recurrence After Ileal Resection
Miguel Regueiro et al.
GASTROENTEROLOGY (2009)
Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort
F. Schnitzler et al.
GUT (2009)
Endpoints for Clinical Trials Evaluating Disease Modification and Structural Damage in Adults with Crohn's Disease
Geert R. D'Haens et al.
INFLAMMATORY BOWEL DISEASES (2009)
Mucosal Healing Predicts Long-term Outcome of Maintenance Therapy with Infliximab in Crohn's Disease
Fabian Schnitzler et al.
INFLAMMATORY BOWEL DISEASES (2009)
Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial
Edward V. Loftus et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
A meta-analysis comparing incidence of recurrence and indication for reoperation after surgery for perforating Versus nonperforating Crohn's disease
Constantinos Simillis et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease:: an open randomised trial
Geert D'Haens et al.
LANCET (2008)
Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: A cohort study
Roopali Bansal Gupta et al.
GASTROENTEROLOGY (2007)
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
Severine Vermeire et al.
GUT (2007)
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial
W. J. Sandborn et al.
GUT (2007)
Maintenance therapy with certolizumab pegol for Crohn's disease
Stefan Schreiber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis
Geert D'Haens et al.
GASTROENTEROLOGY (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
Elana A. Maser et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease
P Rutgeerts et al.
GASTROINTESTINAL ENDOSCOPY (2006)
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis
S Ardizzone et al.
GUT (2006)
Infliximab for induction and maintenance therapy for ulcerative colitis
P Rutgeerts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial
P Rutgeerts et al.
GASTROENTEROLOGY (2005)
Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery
J Cosnes et al.
GUT (2005)
Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD
M Daperno et al.
GASTROINTESTINAL ENDOSCOPY (2004)
Drug interaction between infliximab and azathioprine in patients with Crohn's disease
X Roblin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Early studies on the safety and efficacy of thalidomide for symptomatic inflammatory bowel disease
C Bariol et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2002)
Share Paper
